Medical & research development contract for DHA sttr PH II A2-9110 proposal titled ingestible capsule for vital sign monitoring.
Ended Definitive Contract Awarded Last action
- Contract number
- HT942523C0039
- Awardee
-
Nanohmics Inc. UEI K39ENMXNLA73
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,099,997
Award facts
- Opportunity
-
- HQ003420R2ADB Solicitation number
- Contract value 100% obligated
- $1,099,996.57 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 2 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Austin, TX 78741, USA
- Research
- STTR Phase II
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,099,997 |
About this award
The Defense Health Agency awarded a Phase II Small Business Technology Transfer (STTR) contract to Nanohmics Inc., an Austin, Texas-based technology development company specializing in advanced electronics, sensors, and imaging systems. Under this Definitive Contract with a ceiling value of $1.1M, Nanohmics will develop an ingestible capsule for vital sign monitoring—a medical device designed to enable non-invasive physiological monitoring through an ingested capsule. The contract is set aside for small businesses, reflects firm fixed-price pricing, and carries an ultimate completion date of November 2, 2026. The award, made on July 3, 2023, builds upon Nanohmics' established track record of delivering innovative medical and sensing technologies through federal research and development programs.
This Phase II STTR effort represents a continuation of promising research from Phase I, with the company advancing the ingestible capsule technology toward practical application for military medical readiness and healthcare applications. Nanohmics' demonstrated expertise in sensor development, physiological monitoring systems, and medical device innovation positions the company to deliver a mature prototype capable of real-world deployment. As a small business recipient, Nanohmics brings entrepreneurial agility to the Defense Health Agency's objectives while maintaining partnerships with research institutions, consistent with STTR program requirements that emphasize collaboration between small businesses and academic entities.
Quick answers
Who was awarded contract HT942523C0039?
HT942523C0039 was awarded to Nanohmics Inc. by Defense Health Agency (Department of Defense) on July 3, 2023.
How much is contract HT942523C0039 worth?
The government has obligated $1,099,997 on HT942523C0039.
Was contract HT942523C0039 competed?
The extent of competition for HT942523C0039 was full and open competition after exclusion of sources. The government received 2 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award